Validity of cost-effectiveness models based on randomized clinical trials

Cost-effectiveness studies are widely used to guide prescribing policy in many countries, as part of health technology assessment programmes. However, a new study published this week in PLoS Medicine by Tjeerd-Pieter van Staa and colleagues suggests that cost-effectiveness analyses based on data from randomized controlled trials may not be realistic enough to accurately inform policy.